KerryAnneRogersMD

PubMed

• 50 citations
  Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
  Kerry A. Rogers, Philip A. Thompson, John N. Allan, Morton Coleman, Jeff P. Sharman
  Haematologica. 2021-03-18
• 98 citations
  The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
  Sean D. Reiff, Rose Mantel, Lisa L. Smith, Joseph T. Greene, Elizabeth M. Muhowski
  Cancer Discovery. 2018-08-09
• 594 citations
  Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
  Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M Booth
  The New England Journal of Medicine. 2018-12-01

Abstracts/Posters

• Restoring Functional Deficits in Older Adults with Hematologic Malignancy
  Kerry A. Rogers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia
  Kerry A. Rogers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity
  Kerry A. Rogers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study
  Kerry A Rogers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy
  Kerry A. Rogers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicent... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). 
  2019 ASCO Annual Meeting - 6/1/2019
• Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Change in tumor lysis syndrome risk after lead-in treatment in a phase 1b/2 study of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all